WX-0593
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for WX-0593, covering 2018-01-04 to 2025-06-12. Get the full timeline:
Most recent: Clinical Trial Update: Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer [Phase 2]